Human Apolipoprotein C-I (Apo C1) ELISA Kit

* Hu Y et al. (2021) Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer's disease. J Lipid Res. 62:100014.

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859854/pdf/main.pdf

* Odaka A (2018) Examination of external and internal factors for the pathophysiology of pediatric idiopathic steroid-sensitive nephrotic syndrome. Jichi Medical University.

• https://jichi-ir.repo.nii.ac.jp/?action=pages_view_main&active_action=repository_view_main_item_detail&item_id=460&item_no=1&page_id=13&block_id=21

* Nicola WG et al. (2018) Protective effect of inulin and the integrity of the microvasculature in diabetes mellitus. Biomed. Pharm. J. 11(2):807-813.

• https://biomedpharmajournal.org/vol11no2/protective-effect-of-inulin-and-the-integrity-of-the-microvasculature-in-diabetes-mellitus-by/

* Odaka J et al. (2017) Apolipoprotein C-I Levels Are Associated with the Urinary Protein/Urinary Creatinine Ratio in Pediatric Idiopathic Steroid-Sensitive Nephrotic Syndrome: A Case Control Study. Int J Nephrol. 2017:6392843.

• https://downloads.hindawi.com/journals/ijn/2017/6392843.pdf

* Broek I et al. (2016) Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping. Clin Chem. 62(1):188-97.

• https://www.researchgate.net/profile/Fred-Romijn/publication/284279247_Automated_multiplex_LC-MSMS_assay_for_quantifying_serum_apolipoproteins_A-I_B_C-I_C-II_C-III_and_E_with_qualitative_apolipoprotein_E_phenotyping/links/56a75fac08aeded22e36cc92/Automated-multiplex-LC-MS-MS-assay-for-quantifying-serum-apolipoproteins-A-I-B-C-I-C-II-C-III-and-E-with-qualitative-apolipoprotein-E-phenotyping.pdf

* Basak T et al. (2016) Plasma proteomic analysis of stable coronary artery disease indicates impairment of reverse cholesterol pathway. Sci Rep. 6:28042.

• https://www.nature.com/articles/srep28042.pdf

* Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032332/pdf/pone.0098368.pdf

* Kupervaser-Cohen M (2011) MALDI-Based Serum Peptide Signature Discriminating Stomach and Pancreas Adenocarcinoma Patients from Cancer-Free Controls: Adjustment to Diagnosis with Immuno-Based Assays. Ben-Gurion University of the Negev. PhD Thesis.

• http://aranne5.bgu.ac.il/others/KupervaserCohenMeital.pdf

* Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062.

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139117/pdf/JL2011-271062.pdf

* Cohen M et al. (2011) Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. PLoS One 6(1): e14540

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022591/pdf/pone.0014540.pdf

* Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920018/